Sort   by:  
 Page size 
ProteomicsMulti-Enzymatic Limited Digestion - the Next-Generation Sequencing for Proteomics
An innovative approach merging both the bottom-up and middle-down ideologies to provide fast, robust and comprehensive solutions for proteomics studies. The methodology, referred to as MELD for Multiple-Enzymatic Limited Digestion, capitalizes on a single two-hour long proteolytic step involving the...
ORGANISM(S): Homo sapiens (Human) 
2019-05-08 | PXD009800 | Pride
Ptms Digestibility profile Limited digestion Mass spectrometry Proteolytic method Protein characterization De novo sequencing  mabs 
ProteomicsRevisiting Ehrlichia ruminantium Replication Cycle Using Proteomics : The Host and the Bacterium Perspectives
The Rickettsiales Ehrlichia ruminantium (ER), the causal agent of the fatal tick-borne disease Heartwater, induces severe damage to the vascular endothelium in ruminants. Nevertheless, E. ruminantium-induced pathobiology remains largely unknown. Our work paves the way for understanding this phenomen...
ORGANISM(S): Bos taurus (Bovine) Ehrlichia ruminantium str. Gardel 
2021-07-14 | PXD026092 | Pride
Ehrlichia ruminantium  endothelial cells  host response  immunomodulation  bacterial life cycle  differential protein expression  infection biomarkers  virulence factors 
ProteomicsOsteoarthritis osteoblasts secretome
Osteoarthritis (OA) is the most common joint disease and this is a major cause of joint pain and disability in the aging population. Its etiology is multifactorial (i.e., age, obesity, joint injury, genetic predisposition), and the pathophysiologic process affects the entirety of the joint (Martel-P...
ORGANISM(S): Homo sapiens (Human) 
2018-03-20 | PXD008494 | Pride
Osteoarthritis Secretome Osteoblasts Matrix mineralization Non-collagenous proteins 
ProteomicsDiscovery of biomarker candidates associated with the risk of short- and long-term relapse after infliximab withdrawal in Crohn’s patients: a proteomics-based study
Objective: A subset of Crohn’s disease (CD) patients experiences long-term remission after infliximab withdrawal. Biomarkers are needed to identify those patients. Design: New biomarkers of relapse were searched in the baseline serum of CD patients stopping infliximab when they were under combined t...
ORGANISM(S): Homo Sapiens 
2020-11-02 | PXD019434 | panorama
ProteomicsExternal validation of serum biomarkers predicting short-term and mid/long-term relapse in Crohn’s disease patients stopping infliximab
Background and aims: In Crohn’s disease (CD) patients on combination therapy (infliximab and immunosuppressant) and stopping infliximab (STORI cohort), the risk of short-term (<6 months) and mid/long-term relapse (>6 months) was associated with specific blood protein profiles. Our aim was to test th...
ORGANISM(S): Homo Sapiens 
PXD051233 | panorama
Sort   by:  
 Page size